查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1300999

mRNA疗法的合同开发和製造市场规模、份额、趋势分析报告：按应用、按适应症、按最终用途、按地区、细分趋势，2023-2030年

mRNA Therapeutics Contract Development & Manufacturing Market Size, Share & Trends Analysis Report By Application (Viral Vaccines, Protein Replacement Therapies), By Indication, By End-use, By Region, And Segment Forecasts, 2023 - 2030
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10个工作天内

价格

mRNA 疗法合同开发和製造市场的增长和趋势

Grand View Research, Inc. 的新报告显示，到 2030 年，全球 mRNA 疗法合同开发和製造市场将达到 83.5 亿美元。预计

从 2023 年到 2030 年，市场预计将以 10.5% 的复合年增长率扩张。 mRNA 技术和细胞递送系统的进步，加上其成本效益、易于製造以及针对以前无法治疗的途径的能力，具有彻底改变医学的无限潜力。mRNA 疗法的合同开发和製造 (CDMO) 市场提供了一个利润丰厚的市场成长机会。

不断增加的研发投资和强大的 mRNA 疗法开发产品线也正在推动市场增长。 例如，根据美国国家医学图书馆数据库，截至2021年夏季，美国列出了超过1800项涉及mRNA的临床研究，其中约四分之一是II期试验。 近 60% 的候选药物针对的是实体瘤，30% 是疫苗。 其余的用于治疗自身免疫性疾病、结肠癌、莱姆病等。 此外，mRNA 作为一种潜在的非病毒基因治疗递送方法正在被研究。

此外，为满足未满足的医疗需求而开发新的治疗药物正在改变产品市场。 分子復杂性的增加推动了对研究和製造服务和技术的深入了解的需求，以实现新型分子形式的可持续表达和规模化。 生物偶联、双特异性抗体生产等平台技术可以显着缩短开发和生产时间，帮助客户降低上市时间和投资风险。我们正在寻找熟练的CDMO，他可以 因此，对为製药和生物技术行业设计和製造产品的 CDMO 的需求急剧增加。

随着 mRNA 疫苗的引入和传播，mRNA 技术平台取得了突破，以阻止 2020 年 COVID-19 大流行。 根据 2021 年 10 月发表的一份研究论文，截至 2019 年底，五家专门从事 mRNA 平台的上市公司的总市值为 50 亿美元。 截至2021年8月，其市值超过3000亿美元。 结果表明，COVID-19 的爆发增加了对 mRNA 的需求。

mRNA 合同开发和製造市场报告亮点

  • 传染病细分市场占据主导地位，到 2022 年将占 100% 的收入份额。
  • 由于存在大量正在研究的肿瘤药物，代谢和遗传疾病领域预计将以 11.65% 的复合年增长率增长最快。
  • 由于多种治疗病毒感染 (COVID-19) 的疫苗上市，病毒疫苗领域将在 2022 年占据市场主导地位，销售额份额将达到 100%。
  • 由于对癌症治疗产品开发的日益关注以及 mRNA 在临床试验中的良好结果，预计癌症免疫疗法在预测期内将出现最大的增长
  • 生物技术公司大力推出新冠肺炎 (COVID-19) 疫苗来抗击疫情，这将使生物技术公司在 2022 年拥有最高的市场份额，达到 62.56%。
  • 由于支持 mRNA 需求的临床研究数量不断增加，政府和学术研究机构领域预计在预测期内復合年增长率为 10.81%。
  • 亚太地区预计在预测期内实现最快的增长率，复合年增长率为 9.1%。 印度和中国等发展中国家的製药公司和合同製造组织的数量正在大幅增长，因此亚太地区很可能在不久的将来超过欧洲和北美。

内容

第一章调查方法及范围

  • 市场细分和范围
  • 市场定义
  • 信息获取
    • 购买的数据库
    • GVR 内部数据库
    • 二手信息和第三方观点
    • 初步调查
    • 初步调查的详细信息
  • 信息分析
    • 数据分析模型
  • 市场形成和数据可视化
    • 产品流分析
  • 验证和发布数据
  • 全球市场复合年增长率计算
  • 辅助信息列表
  • 主要信息列表

第 2 章执行摘要

  • 市场概况
  • 分段快照
  • 衝突注意事项概览

第三章市场变量、趋势和范围

  • 市场血统
    • 母公司市场分析
    • 补充市场分析
  • mRNA 合同开发和製造 (CDMO) 市场 - 市场动态
    • 市场驱动因素分析
    • 市场製约因素分析
  • 商业环境工具分析 mRNA 治疗药物合同开发和製造 (CDMO) 市场
    • 波特五力分析
    • 杵分析
  • COVID-19 感染的影响分析

第 4 章 mRNA 治疗的合同开发和製造 (CDMO) 市场、按应用进行评估和趋势分析

  • mRNA 合同开发和製造 (CDMO) 市场，按应用划分的要点
  • mRNA 治疗合同开发和製造 (CDMO) 市场、应用趋势和市场份额分析，2022 年和 2030 年
  • 病毒疫苗
    • 2020-2030 年病毒疫苗开发市场预估与预测（百万美元）
  • 蛋白质替代疗法
    • 2020-2030 年蛋白质替代疗法市场估计和预测（百万美元）
  • 癌症免疫疗法
    • 2020-2030 年癌症免疫治疗市场估计和预测（百万美元）

第五章 mRNA治疗药物合同开发和製造（CDMO）市场适应症的估计和趋势分析

  • mRNA 合同开发和製造 (CDMO) 市场，按指标划分的要点
  • 2022 年和 2030 年 mRNA 治疗合同开发和製造 (CDMO) 市场、趋势和市场份额分析
  • 感染
    • 2020-2030 年传染病市场估计和预测（百万美元）
  • 代谢和遗传疾病
    • 2020-2030 年代谢和遗传疾病市场估计和预测（百万美元）
  • 心血管疾病和脑血管疾病
    • 2020-2030 年心脑血管疾病市场估算和预测（百万美元）

第 6 章 mRNA 治疗的合同开发和製造 (CDMO) 市场的最终用途估计和趋势分析

  • mRNA 合同开发和製造 (CDMO) 市场，按最终用途划分的要点
  • 2022 年和 2030 年 mRNA 治疗合同开发和製造 (CDMO) 市场（按最终用途和市场份额分析）
  • 生物科技公司
    • 2020-2030 年创新市场估算和预测（百万美元）
  • 製药公司
    • 2020-2030 年製药公司市场估算和预测（百万美元）
  • 政府和学术研究机构
    • 政府和学术研究机构 2020-2030 年市场估计和预测（百万美元）

第 7 章 mRNA 治疗合同开发和製造 (CDMO) 市场的区域分析

  • 2022 年和 2030 年 mRNA 疗法合同开发和製造 (CDMO) 区域市场份额分析
  • 北美
    • 美国
    • 加拿大
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 意大利
    • 西班牙
    • 丹麦
    • 瑞典
    • 挪威
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 韩国
    • 澳大利亚
    • 泰国
    • 韩国
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 阿根廷
    • 哥伦比亚
    • 智利
  • MEA
    • 南非
    • 沙特阿拉伯
    • 阿拉伯联合酋长国
    • 科威特

第 8 章竞争格局

  • 公司分类
  • 战略规划
  • 公司简介/列表
    • Danaher（Aldevron）
    • Recipharm AB
    • Biomay AG
    • Samsung Biologics
    • Lonza
    • Catalent , Inc.
    • Bio-Indication Inc,
    • eTheRNA
    • Kaneka Eurogentec SA
    • TriLink BioTechnologies
    • ApexBio Technology
    • BioNTech SE.
    • Biocina
Product Code: GVR-4-68040-083-7

mRNA Therapeutics Contract Development & Manufacturing Market Growth & Trends

The global mRNA therapeutics contract development and manufacturing market is expected to reach USD 8.35 billion by 2030, according to a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 10.5% from 2023 to 2030. Advances in mRNA technologies and cellular delivery systems coupled with their cost effectiveness, manufacturing simplicity, and ability to target previously undruggable pathways have limitless potential that could revolutionize medicine, representing lucrative growth opportunities for the mRNA therapeutics contract development and manufacturing (CDMO) market.

Increasing investments in R&D for the development of mRNA therapeutics and a strong product pipeline are also propelling the growth of the market. For instance, according to the U.S. National Library of Medicine database, as of summer 2021, over 1,800 clinical studies involving mRNA were listed in the U.S. Approximately one-quarter of which were in phase II. Nearly 60% of candidates target solid tumors, while 30% of candidates are vaccines. The remaining ones are used to treat conditions like autoimmune disorders, colorectal cancer, and Lyme disease. Additionally, mRNA is being researched as a possible nonviral gene therapy delivery method.

In addition, the development of novel therapeutics to address unmet medical needs is altering the market for products. The need for in-depth knowledge in research and manufacturing services, as well as the technology to enable sustainable expression and scale-up of novel molecular formats, is being driven by the rise in molecular complexity. Platform technologies, such as those for bioconjugation or the creation of bispecific antibodies, can drastically shorten development and production times, and customers are looking for skilled CDMOs who can assist them shorten the time to market and reducing investment risk. Consequently, the need for CDMOs to design and produce goods for the pharmaceutical and biotechnology industries is growing exponentially.

With the introduction and widespread usage of mRNA vaccinations to stop the COVID-19 pandemic in 2020, mRNA technology platforms had a breakthrough. At the end of 2019, the combined market capitalization of the five publicly listed firms that specialize in mRNA platforms was USD 5 billion, according to a research paper released in October 2021. That capitalization exceeded USD 300 billion as of August 2021. Consequently, indicating that the COVID-19 outbreak has increased the demand for mRNA.

mRNA Therapeutics Contract Development & Manufacturing Market Report Highlights

  • The infectious diseases segment dominated the market and accounted for the entire revenue share of 100% in 2022, due to the launch of various COVID-19 vaccines that primarily used mRNA
  • The metabolic and genetic diseases segment is anticipated to undergo maximum growth with a CAGR of 11.65%, due to the presence of a strong pipeline under research for cancer therapeutics
  • Viral vaccines segment dominated the market in 2022 and contributed towards the entire revenue share of 100% owing to the availability and launch of various vaccines for the treatment of viral infection (COVID-19)
  • Cancer immunotherapies is expected to experience maximum growth over the forecast period due to increased focus to develop products for the treatment of cancer and favorable results presented by mRNA for the same in clinical trials
  • Biotech companies held the highest market share of 62.56% in 2022 due to vigorous efforts by these companies to launch COVID-19 vaccines to control the pandemic
  • The Government & Academic Research Institutes segment is anticipated to witness the fastest CAGR of 10.81% over the forecast owing to the rise in the number of clinical research supporting the demand for mRNA
  • In Asia Pacific, the market is expected to register the fastest growth rate of 9.1% CAGR over the forecast period. Due to the extremely rising number of pharmaceutical companies and contract manufacturing organizations in developing countries like India and China, Asia Pacific is likely to overtake Europe and North America in the near future

Table of Content

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Market Definitions
  • 1.3. Information Procurement
    • 1.3.1. Purchased Database
    • 1.3.2. GVR's Internal Database
    • 1.3.3. Secondary Sources & Third-Party Perspectives
    • 1.3.4. Primary Research
    • 1.3.5. Details of Primary Research
  • 1.4. Information Analysis
    • 1.4.1. Data Analysis Models
  • 1.5. Market Formulation & Data Visualization
    • 1.5.1. Commodity Flow Analysis
      • 1.5.1.1. Approach 1 Commodity flow approach
      • 1.5.1.2. Approach 2 Country wise market estimation using bottom up approach
  • 1.6. Data Validation & Publishing
  • 1.7. Global Market CAGR Calculation
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segmental Snapshot
  • 2.3. Competitive Insights Snapshot

Chapter 3. Market Variables, Trends, and Scope

  • 3.1. Market Lineage
    • 3.1.1. Parent Market Analysis
    • 3.1.2. Ancillary Market Analysis
  • 3.2. mRNA Therapeutics Contract Development and Manufacturing (CDMO) Market - Market Dynamics
    • 3.2.1. Market Driver Analysis
      • 3.2.1.1. High adoption of mRNA in vaccines
      • 3.2.1.2. High number of researches in mRNA therapeutics
      • 3.2.1.3. Fundings for mRNA researches
    • 3.2.2. Market Restraint Analysis
      • 3.2.2.1. High cost of research
      • 3.2.2.2. Availability of substitute therapy at low cost.
  • 3.3. Business Environmental Tools Analysis mRNA Therapeutics Contract Development and Manufacturing (CDMO) Market
    • 3.3.1. Porter's Five Forces Analysis
    • 3.3.2. PESTLE Analysis
  • 3.4. COVID-19 Impact Analysis

Chapter 4. mRNA Therapeutics Contract Development and Manufacturing (CDMO) Market Application Estimates & Trend Analysis

  • 4.1. mRNA Therapeutics Contract Development and Manufacturing (CDMO) Market, By Application Key Takeaways
  • 4.2. mRNA Therapeutics Contract Development and Manufacturing (CDMO) Market Application Movement & Market Share Analysis, 2022 & 2030
  • 4.3. Viral Vaccines
    • 4.3.1. Viral Vaccines Development Market Estimates And Forecasts, 2020 - 2030 (USD Million)
  • 4.4. Protein Replacement Therapies
    • 4.4.1. Protein Replacement Therapies Market Estimates And Forecasts, 2020 - 2030 (USD Million)
  • 4.5. Cancer Immunotherapies
    • 4.5.1. Cancer Immunotherapies Market Estimates And Forecasts, 2020 - 2030 (USD Million)

Chapter 5. mRNA Therapeutics Contract Development and Manufacturing (CDMO) Market Indication Estimates & Trend Analysis

  • 5.1. mRNA Therapeutics Contract Development and Manufacturing (CDMO) Market, By Indication Key Takeaways
  • 5.2. mRNA Therapeutics Contract Development and Manufacturing (CDMO) Market Indication Movement & Market Share Analysis, 2022 & 2030
  • 5.3. Infectious Diseases
    • 5.3.1. Infectious Diseases Market Estimates And Forecasts, 2020 - 2030 (USD Million)
  • 5.4. Metabolic & Genetic Diseases
    • 5.4.1. Metabolic & Genetic Diseases Market Estimates And Forecasts, 2020 - 2030 (USD Million)
  • 5.5. Cardiovascular & Cerebrovascular Diseases
    • 5.5.1. Cardiovascular & Cerebrovascular Diseases Market Estimates And Forecasts, 2020 - 2030 (USD Million)

Chapter 6. mRNA Therapeutics Contract Development and Manufacturing (CDMO) Market End Use Estimates & Trend Analysis

  • 6.1. mRNA Therapeutics Contract Development and Manufacturing (CDMO) Market, By End Use Key Takeaways
  • 6.2. mRNA Therapeutics Contract Development and Manufacturing (CDMO) Market End Use Movement & Market Share Analysis, 2022 & 2030
  • 6.3. Biotech Companies
    • 6.3.1. Innovative Market Estimates And Forecasts, 2020 - 2030 (USD Million)
  • 6.4. Pharmaceutical companies
    • 6.4.1. Pharmaceutical companies Market Estimates And Forecasts, 2020 - 2030 (USD Million)
  • 6.5. Government & Academic Research Institutes
    • 6.5.1. Government & Academic Research Institutes Market Estimates And Forecasts, 2020 - 2030 (USD Million)

Chapter 7. mRNA Therapeutics Contract Development and Manufacturing (CDMO) Market Regional Analysis

  • 7.1. mRNA Therapeutics Contract Development and Manufacturing (CDMO) Regional market share analysis, 2022 & 2030
  • 7.2. North America
    • 7.2.1. North America Market estimates and forecast, 2020 - 2030
    • 7.2.2. U.S.
      • 7.2.2.1. U.S. Market estimates and forecast, 2020 - 2030
    • 7.2.3. Canada
      • 7.2.3.1. Canada Market estimates and forecast, 2020 - 2030
  • 7.3. Europe
    • 7.3.1. Europe Market estimates and forecast, 2020 - 2030
    • 7.3.2. UK
      • 7.3.2.1. UK Market estimates and forecast, 2020 - 2030
    • 7.3.3. Germany
      • 7.3.3.1. Germany Market estimates and forecast, 2020 - 2030
    • 7.3.4. France
      • 7.3.4.1. France Market estimates and forecast, 2020 - 2030
    • 7.3.5. Italy
      • 7.3.5.1. Italy Market estimates and forecast, 2020 - 2030
    • 7.3.6. Spain
      • 7.3.6.1. Spain Market estimates and forecast, 2020 - 2030
    • 7.3.7. Denmark
      • 7.3.7.1. Denmark Market estimates and forecast, 2020 - 2030
    • 7.3.8. Sweden
      • 7.3.8.1. Sweden Market estimates and forecast, 2020 - 2030
    • 7.3.9. Norway
      • 7.3.9.1. Norway Market estimates and forecast, 2020 - 2030
  • 7.4. Asia Pacific
    • 7.4.1. Asia Pacific Market estimates and forecast, 2020 - 2030
    • 7.4.2. Japan
      • 7.4.2.1. Japan Market estimates and forecast, 2020 - 2030
    • 7.4.3. China
      • 7.4.3.1. China Market estimates and forecast, 2020 - 2030
    • 7.4.4. India
      • 7.4.4.1. India Market estimates and forecast, 2020 - 2030
    • 7.4.5. South Korea
      • 7.4.5.1. South Korea Market estimates and forecast, 2020 - 2030
    • 7.4.6. Australia
      • 7.4.6.1. Australia Market estimates and forecast, 2020 - 2030
    • 7.4.7. Thailand
      • 7.4.7.1. Thailand Market estimates and forecast, 2020 - 2030
    • 7.4.8. South Korea
      • 7.4.8.1. South Korea Market estimates and forecast, 2020 - 2030
  • 7.5. Latin America
    • 7.5.1. Latin America Market estimates and forecast, 2020 - 2030
    • 7.5.2. Brazil
      • 7.5.2.1. Brazil Market estimates and forecast, 2020 - 2030
    • 7.5.3. Mexico
      • 7.5.3.1. Mexico Market estimates and forecast, 2020 - 2030
    • 7.5.4. Argentina
      • 7.5.4.1. Argentina Market estimates and forecast, 2020 - 2030
    • 7.5.5. Colombia
      • 7.5.5.1. Colombia Market estimates and forecast, 2020 - 2030
    • 7.5.6. Chile
      • 7.5.6.1. Chile Market estimates and forecast, 2020 - 2030
  • 7.6. MEA
    • 7.6.1. MEA Market estimates and forecast, 2020 - 2030
    • 7.6.2. South Africa
      • 7.6.2.1. South Africa Market estimates and forecast, 2020 - 2030
    • 7.6.3. Saudi Arabia
      • 7.6.3.1. Saudi Arabia Market estimates and forecast, 2020 - 2030
    • 7.6.4. UAE
      • 7.6.4.1. UAE Market estimates and forecast, 2020 - 2030
    • 7.6.5. Kuwait
      • 7.6.5.1. Kuwait Market estimates and forecast, 2020 - 2030

Chapter 8. Competitive Landscape

  • 8.1. Company Categorization
  • 8.2. Strategy Mapping
  • 8.3. Company Profiles/Listing
    • 8.3.1. Danaher (Aldevron)
      • 8.3.1.1. Overview
      • 8.3.1.2. Financial Performance
      • 8.3.1.3. Service Benchmarking
      • 8.3.1.4. Strategic Initiatives
    • 8.3.2. Recipharm AB
      • 8.3.2.1. Overview
      • 8.3.2.2. Financial Performance
      • 8.3.2.3. Service Benchmarking
      • 8.3.2.4. Strategic Initiatives
    • 8.3.3. Biomay AG
      • 8.3.3.1. Overview
      • 8.3.3.2. Financial Performance
      • 8.3.3.3. Service Benchmarking
      • 8.3.3.4. Strategic Initiatives
    • 8.3.4. Samsung Biologics
      • 8.3.4.1. Overview
      • 8.3.4.2. Financial Performance
      • 8.3.4.3. Service Benchmarking
      • 8.3.4.4. Strategic Initiatives
    • 8.3.5. Lonza
      • 8.3.5.1. Overview
      • 8.3.5.2. Financial Performance
      • 8.3.5.3. Service Benchmarking
      • 8.3.5.4. Strategic Initiatives
    • 8.3.6. Catalent , Inc.
      • 8.3.6.1. Overview
      • 8.3.6.2. Financial Performance
      • 8.3.6.3. Service Benchmarking
      • 8.3.6.4. Strategic Initiatives
    • 8.3.7. Bio-Indication Inc,
      • 8.3.7.1. Overview
      • 8.3.7.2. Financial Performance
      • 8.3.7.3. Service Benchmarking
      • 8.3.7.4. Strategic Initiatives
    • 8.3.8. eTheRNA
      • 8.3.8.1. Overview
      • 8.3.8.2. Financial Performance
      • 8.3.8.3. Service Benchmarking
      • 8.3.8.4. Strategic Initiatives
    • 8.3.9. Kaneka Eurogentec S.A
      • 8.3.9.1. Overview
      • 8.3.9.2. Financial Performance
      • 8.3.9.3. Service Benchmarking
      • 8.3.9.4. Strategic Initiatives
    • 8.3.10. TriLink BioTechnologies
      • 8.3.10.1. Overview
      • 8.3.10.2. Financial Performance
      • 8.3.10.3. Service Benchmarking
      • 8.3.10.4. Strategic Initiatives
    • 8.3.11. ApexBio Technology
      • 8.3.11.1. Overview
      • 8.3.11.2. Financial Performance
      • 8.3.11.3. Service Benchmarking
      • 8.3.11.4. Strategic Initiatives
    • 8.3.12. BioNTech SE.
      • 8.3.12.1. Overview
      • 8.3.12.2. Financial Performance
      • 8.3.12.3. Service Benchmarking
      • 8.3.12.4. Strategic Initiatives
    • 8.3.13. Biocina
      • 8.3.13.1. Overview
      • 8.3.13.2. Financial Performance
      • 8.3.13.3. Service Benchmarking
      • 8.3.13.4. Strategic Initiatives

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of abbreviations
  • Table 3 Global mRNA therapeutics contract development and manufacturing (CDMO) market, by application, 2020 - 2030 (USD Million)
  • Table 4 Global mRNA therapeutics contract development and manufacturing (CDMO) market, by indication, 2020 - 2030 (USD Million)
  • Table 5 Global mRNA therapeutics contract development and manufacturing (CDMO) market, by end user, 2020 - 2030 (USD Million)
  • Table 6 Global mRNA therapeutics contract development and manufacturing (CDMO) market, by region, 2020 - 2030 (USD Million)
  • Table 7 North America mRNA therapeutics contract development and manufacturing (CDMO) market, by country, 2020 - 2030 (USD Million)
  • Table 8 North America mRNA therapeutics contract development and manufacturing (CDMO) market, by application, 2020 - 2030 (USD Million)
  • Table 9 North America mRNA therapeutics contract development and manufacturing (CDMO) market, by indication, 2020 - 2030 (USD Million)
  • Table 10 North America mRNA therapeutics contract development and manufacturing (CDMO) market, by end user, 2020 - 2030 (USD Million)
  • Table 11 U.S. mRNA therapeutics contract development and manufacturing (CDMO) market, by application, 2020 - 2030 (USD Million)
  • Table 12 U.S. mRNA therapeutics contract development and manufacturing (CDMO) market, by indication, 2020 - 2030 (USD Million)
  • Table 13 U.S. mRNA therapeutics contract development and manufacturing (CDMO) market, by end user, 2020 - 2030 (USD Million)
  • Table 14 Canada mRNA therapeutics contract development and manufacturing (CDMO) market, by application, 2020-2030, (USD million
  • Table 15 Canada mRNA therapeutics contract development and manufacturing (CDMO) market, by indication, 2020 - 2030 (USD Million)
  • Table 16 Canada mRNA therapeutics contract development and manufacturing (CDMO) market, by end user, 2020 - 2030 (USD Million)
  • Table 17 Europe mRNA therapeutics contract development and manufacturing (CDMO) market, by country, 2020 - 2030 (USD Million)
  • Table 18 Europe mRNA therapeutics contract development and manufacturing (CDMO) market, by application, 2020 - 2030 (USD Million)
  • Table 19 Europe mRNA therapeutics contract development and manufacturing (CDMO) market, by indication, 2020 - 2030 (USD Million)
  • Table 20 Europe mRNA therapeutics contract development and manufacturing (CDMO) market, by end user, 2020 - 2030 (USD Million)
  • Table 21 Germany mRNA therapeutics contract development and manufacturing (CDMO) market, by application, 2020 - 2030 (USD Million)
  • Table 22 Germany mRNA therapeutics contract development and manufacturing (CDMO) market, by indication, 2020 - 2030 (USD Million)
  • Table 23 Germany mRNA therapeutics contract development and manufacturing (CDMO) market, by end user, 2020 - 2030 (USD Million)
  • Table 24 UK mRNA therapeutics contract development and manufacturing (CDMO) market, by application, 2020 - 2030 (USD Million)
  • Table 25 UK mRNA therapeutics contract development and manufacturing (CDMO) market, by indication, 2020 - 2030 (USD Million)
  • Table 26 UK mRNA therapeutics contract development and manufacturing (CDMO) market, by end user, 2020 - 2030 (USD Million)
  • Table 27 France mRNA therapeutics contract development and manufacturing (CDMO) market, by application, 2020 - 2030 (USD Million)
  • Table 28 France mRNA therapeutics contract development and manufacturing (CDMO) market, by indication, 2020 - 2030 (USD Million)
  • Table 29 France mRNA therapeutics contract development and manufacturing (CDMO) market, by end user, 2020 - 2030 (USD Million)
  • Table 30 France mRNA therapeutics contract development and manufacturing (CDMO) market, by application, 2020 - 2030 (USD Million)
  • Table 31 Italy mRNA therapeutics contract development and manufacturing (CDMO) market, by indication, 2020 - 2030 (USD Million)
  • Table 32 Italy mRNA therapeutics contract development and manufacturing (CDMO) market, by end user, 2020 - 2030 (USD Million)
  • Table 33 Spain mRNA therapeutics contract development and manufacturing (CDMO) market, by application, 2020 - 2030 (USD Million)
  • Table 34 Spain mRNA therapeutics contract development and manufacturing (CDMO) market, by indication, 2020 - 2030 (USD Million)
  • Table 35 Spain mRNA therapeutics contract development and manufacturing (CDMO) market, by end user, 2020 - 2030 (USD Million)
  • Table 36 Denmark mRNA therapeutics contract development and manufacturing (CDMO) market, by application, 2020 - 2030 (USD Million)
  • Table 37 Denmark mRNA therapeutics contract development and manufacturing (CDMO) market, by indication, 2020 - 2030 (USD Million)
  • Table 38 Denmark mRNA therapeutics contract development and manufacturing (CDMO) market, by end user, 2020 - 2030 (USD Million)
  • Table 39 Sweden mRNA therapeutics contract development and manufacturing (CDMO) market, by application, 2020 - 2030 (USD Million)
  • Table 40 Sweden mRNA therapeutics contract development and manufacturing (CDMO) market, by indication, 2020 - 2030 (USD Million)
  • Table 41 Sweden mRNA therapeutics contract development and manufacturing (CDMO) market, by end user, 2020 - 2030 (USD Million)
  • Table 42 Norway mRNA therapeutics contract development and manufacturing (CDMO) market, by application, 2020 - 2030 (USD Million)
  • Table 43 Norway mRNA therapeutics contract development and manufacturing (CDMO) market, by indication, 2020 - 2030 (USD Million)
  • Table 44 Norway mRNA therapeutics contract development and manufacturing (CDMO) market, by end user, 2020 - 2030 (USD Million)
  • Table 45 Asia Pacific mRNA therapeutics contract development and manufacturing (CDMO) market, by country, 2020 - 2030 (USD Million)
  • Table 46 Asia Pacific mRNA therapeutics contract development and manufacturing (CDMO) market, by application, 2020 - 2030 (USD Million)
  • Table 47 Asia Pacific mRNA therapeutics contract development and manufacturing (CDMO) market, by indication, 2020 - 2030 (USD Million)
  • Table 48 Asia Pacific mRNA therapeutics contract development and manufacturing (CDMO) market, by end user, 2020 - 2030 (USD Million)
  • Table 49 Japan mRNA therapeutics contract development and manufacturing (CDMO) market, by application, 2020 - 2030 (USD Million)
  • Table 50 Japan mRNA therapeutics contract development and manufacturing (CDMO) market, by indication, 2020 - 2030 (USD Million)
  • Table 51 Japan mRNA therapeutics contract development and manufacturing (CDMO) market, by end user, 2020 - 2030 (USD Million)
  • Table 52 China mRNA therapeutics contract development and manufacturing (CDMO) market, by application, 2020 - 2030 (USD Million)
  • Table 53 China mRNA therapeutics contract development and manufacturing (CDMO) market, by indication, 2020 - 2030 (USD Million)
  • Table 54 China mRNA therapeutics contract development and manufacturing (CDMO) market, by end user, 2020 - 2030 (USD Million)
  • Table 55 India mRNA therapeutics contract development and manufacturing (CDMO) market, by application, 2020 - 2030 (USD Million)
  • Table 56 India mRNA therapeutics contract development and manufacturing (CDMO) market, by indication, 2020 - 2030 (USD Million)
  • Table 57 India mRNA therapeutics contract development and manufacturing (CDMO) market, by end user, 2020 - 2030 (USD Million)
  • Table 58 Australia mRNA therapeutics contract development and manufacturing (CDMO) market, by application, 2020 - 2030 (USD Million)
  • Table 59 Australia mRNA therapeutics contract development and manufacturing (CDMO) market, by indication, 2020 - 2030 (USD Million)
  • Table 60 Australia mRNA therapeutics contract development and manufacturing (CDMO) market, by end user, 2020 - 2030 (USD Million)
  • Table 61 South Korea mRNA therapeutics contract development and manufacturing (CDMO) market, by application, 2020 - 2030 (USD Million)
  • Table 62 South Korea mRNA therapeutics contract development and manufacturing (CDMO) market, by indication, 2020 - 2030 (USD Million)
  • Table 63 South Korea mRNA therapeutics contract development and manufacturing (CDMO) market, by end user, 2020 - 2030 (USD Million)
  • Table 64 Thailand mRNA therapeutics contract development and manufacturing (CDMO) market, by application, 2020 - 2030 (USD Million)
  • Table 65 Thailand mRNA therapeutics contract development and manufacturing (CDMO) market, by indication, 2020 - 2030 (USD Million)
  • Table 66 Thailand mRNA therapeutics contract development and manufacturing (CDMO) market, by end user, 2020 - 2030 (USD Million)
  • Table 67 Latin America mRNA therapeutics contract development and manufacturing (CDMO) market, by country, 2020 - 2030 (USD Million)
  • Table 68 Latin America mRNA therapeutics contract development and manufacturing (CDMO) market, by application, 2020 - 2030 (USD Million)
  • Table 69 Latin America mRNA therapeutics contract development and manufacturing (CDMO) market, by indication, 2020 - 2030 (USD Million)
  • Table 70 Latin America mRNA therapeutics contract development and manufacturing (CDMO) market, by end user, 2020 - 2030 (USD Million)
  • Table 71 Brazil mRNA therapeutics contract development and manufacturing (CDMO) market, by application, 2020 - 2030 (USD Million)
  • Table 72 Brazil mRNA therapeutics contract development and manufacturing (CDMO) market, by indication, 2020 - 2030 (USD Million)
  • Table 73 Brazil mRNA therapeutics contract development and manufacturing (CDMO) market, by end user, 2020 - 2030 (USD Million)
  • Table 74 Mexico mRNA therapeutics contract development and manufacturing (CDMO) market, by application, 2020 - 2030 (USD Million)
  • Table 75 Mexico mRNA therapeutics contract development and manufacturing (CDMO) market, by indication, 2020 - 2030 (USD Million)
  • Table 76 Mexico mRNA therapeutics contract development and manufacturing (CDMO) market, by end user, 2020 - 2030 (USD Million)
  • Table 77 Argentina mRNA therapeutics contract development and manufacturing (CDMO) market, by application, 2020 - 2030 (USD Million)
  • Table 78 Argentina mRNA therapeutics contract development and manufacturing (CDMO) market, by indication, 2020 - 2030 (USD Million)
  • Table 79 Argentina mRNA therapeutics contract development and manufacturing (CDMO) market, by end user, 2020 - 2030 (USD Million)
  • Table 80 Middle East & Africa mRNA therapeutics contract development and manufacturing (CDMO) market, by country, 2020 - 2030 (USD Million)
  • Table 81 Middle East & Africa mRNA therapeutics contract development and manufacturing (CDMO) market, by application, 2020 - 2030 (USD Million)
  • Table 82 Middle East & Africa mRNA therapeutics contract development and manufacturing (CDMO) market, by indication, 2020 - 2030 (USD Million)
  • Table 83 Middle East & Africa mRNA therapeutics contract development and manufacturing (CDMO) market, by end user, 2020 - 2030 (USD Million)
  • Table 84 South Africa mRNA therapeutics contract development and manufacturing (CDMO) market, by application, 2020 - 2030 (USD Million)
  • Table 85 South Africa mRNA therapeutics contract development and manufacturing (CDMO) market, by indication, 2020 - 2030 (USD Million)
  • Table 86 South Africa mRNA therapeutics contract development and manufacturing (CDMO) market, by end user, 2020 - 2030 (USD Million)
  • Table 87 Saudi Arabia mRNA therapeutics contract development and manufacturing (CDMO) market, by application, 2020 - 2030 (USD Million)
  • Table 88 Saudi Arabia mRNA therapeutics contract development and manufacturing (CDMO) market, by indication, 2020 - 2030 (USD Million)
  • Table 89 Saudi Arabia mRNA therapeutics contract development and manufacturing (CDMO) market, by application, 2020 - 2030 (USD Million)
  • Table 90 Saudi Arabia mRNA therapeutics contract development and manufacturing (CDMO) market, by end user, 2020 - 2030 (USD Million)
  • Table 91 UAE mRNA therapeutics contract development and manufacturing (CDMO) market, by application, 2020 - 2030 (USD Million)
  • Table 92 UAE mRNA therapeutics contract development and manufacturing (CDMO) market, by indication, 2020 - 2030 (USD Million)
  • Table 93 UAE mRNA therapeutics contract development and manufacturing (CDMO) market, by end user, 2020 - 2030 (USD Million)
  • Table 94 Kuwait mRNA therapeutics contract development and manufacturing (CDMO) market, by application, 2020 - 2030 (USD Million)
  • Table 95 Kuwait mRNA therapeutics contract development and manufacturing (CDMO) market, by indication, 2020 - 2030 (USD Million)
  • Table 96 Kuwait mRNA therapeutics contract development and manufacturing (CDMO) market, by end user, 2020 - 2030 (USD Million)

List of Figures

  • Fig. 1 mRNA therapeutics contract development and manufacturing (CDMO) market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 QFD modeling for market share assessment
  • Fig. 8 Market formulation & validation
  • Fig. 9 Market snapshot
  • Fig. 10 Segment snapshot
  • Fig. 11 Competitive landscape snapshot
  • Fig. 12 Parent market outlook
  • Fig. 13 Related/ancillary market outlook
  • Fig. 14 mRNA Therapeutics Contract Development and Manufacturing (CDMO) - Industry value chain analysis
  • Fig. 15 mRNA therapeutics contract development and manufacturing (CDMO) market driver analysis
  • Fig. 16 mRNA therapeutics contract development and manufacturing (CDMO) market restraint analysis
  • Fig. 17 mRNA therapeutics contract development and manufacturing (CDMO) market: Porter's analysis
  • Fig. 18 mRNA therapeutics contract development and manufacturing (CDMO) market: PESTLE analysis
  • Fig. 19 mRNA therapeutics contract development and manufacturing (CDMO) market: application outlook and key takeaways
  • Fig. 20 mRNA therapeutics contract development and manufacturing (CDMO) market: application market share analysis, 2022 - 2030
  • Fig. 21 Global viral vaccines development market, 2020 - 2030 (USD Million)
  • Fig. 22 Global protein replacement therapies market, 2020 - 2030 (USD Million)
  • Fig. 23 Global cancer immunotherapies market, 2020 - 2030 (USD Million)
  • Fig. 24 mRNA therapeutics contract development and manufacturing (CDMO) market: Indication outlook and key takeaways
  • Fig. 25 mRNA therapeutics contract development and manufacturing (CDMO) market: Indication market share analysis, 2022 - 2030
  • Fig. 26 Global infectious diseases market, 2020 - 2030 (USD Million)
  • Fig. 27 Global metabolic & genetic diseases market, 2020 - 2030 (USD Million)
  • Fig. 28 Global cardiovascular and cerebrovascular diseases market, 2020 - 2030 (USD Million)
  • Fig. 29 mRNA therapeutics contract development and manufacturing (CDMO) market: End-user outlook and key takeaways
  • Fig. 30 mRNA therapeutics contract development and manufacturing (CDMO) market: End-user market share analysis, 2022 - 2030
  • Fig. 31 Global biotech companies market, 2020 - 2030 (USD Million)
  • Fig. 32 Global pharmaceutical companies market, 2020 - 2030 (USD Million)
  • Fig. 33 Global government & academic research institutes market, 2020 - 2030 (USD Million)
  • Fig. 34 Regional marketplace: Key takeaways
  • Fig. 35 Regional marketplace: Key takeaways
  • Fig. 36 North America mRNA therapeutics contract development and manufacturing (CDMO) market estimates and forecast, 2020 - 2030 (USD Million)
  • Fig. 37 U.S. key country dynamics
  • Fig. 38 U.S. mRNA therapeutics contract development and manufacturing (CDMO) market estimates and forecast, 2020 - 2030 (USD Million)
  • Fig. 39 Canada key country dynamics
  • Fig. 40 Canada mRNA therapeutics contract development and manufacturing (CDMO) market, 2020 - 2030 (USD Million)
  • Fig. 41 Europe mRNA therapeutics contract development and manufacturing (CDMO) market estimates and forecast, 2020 - 2030 (USD Million)
  • Fig. 42 Germany key country dynamics
  • Fig. 43 Germany mRNA therapeutics contract development and manufacturing (CDMO) market estimates and forecast, 2020 - 2030 (USD Million)
  • Fig. 44 UK key country dynamics
  • Fig. 45 UK mRNA therapeutics contract development and manufacturing (CDMO) market estimates and forecast, 2020 - 2030 (USD Million)
  • Fig. 46 France key country dynamics
  • Fig. 47 France mRNA therapeutics contract development and manufacturing (CDMO) market estimates and forecast, 2020 - 2030 (USD Million)
  • Fig. 48 Italy key country dynamics
  • Fig. 49 Italy mRNA therapeutics contract development and manufacturing (CDMO) market estimates and forecast, 2020 - 2030 (USD Million)
  • Fig. 50 Spain key country dynamics
  • Fig. 51 Spain mRNA therapeutics contract development and manufacturing (CDMO) market estimates and forecast, 2020 - 2030 (USD Million)
  • Fig. 52 Denmark key country dynamics
  • Fig. 53 Denmark mRNA therapeutics contract development and manufacturing (CDMO) market estimates and forecast, 2020 - 2030 (USD Million)
  • Fig. 54 Sweden key country dynamics
  • Fig. 55 Sweden mRNA therapeutics contract development and manufacturing (CDMO) market estimates and forecast, 2020 - 2030 (USD Million)
  • Fig. 56 Norway key country dynamics
  • Fig. 57 Norway mRNA therapeutics contract development and manufacturing (CDMO) market estimates and forecast, 2020 - 2030 (USD Million)
  • Fig. 58 Asia-Pacific mRNA therapeutics contract development and manufacturing (CDMO) market estimates and forecast, 2020 - 2030 (USD Million)
  • Fig. 59 Japan key country dynamics
  • Fig. 60 Japan mRNA therapeutics contract development and manufacturing (CDMO) market estimates and forecast, 2020 - 2030 (USD Million)
  • Fig. 61 China key country dynamics
  • Fig. 62 China mRNA therapeutics contract development and manufacturing (CDMO) market estimates and forecast, 2020 - 2030 (USD Million)
  • Fig. 63 India key country dynamics
  • Fig. 64 India mRNA therapeutics contract development and manufacturing (CDMO) market estimates and forecast, 2020 - 2030 (USD Million)
  • Fig. 65 Australia key country dynamics
  • Fig. 66 Australia mRNA therapeutics contract development and manufacturing (CDMO) market estimates and forecast, 2020 - 2030 (USD Million)
  • Fig. 67 Thailand key country dynamics
  • Fig. 68 Thailand mRNA therapeutics contract development and manufacturing (CDMO) market estimates and forecast, 2020 - 2030 (USD Million)
  • Fig. 69 South Korea key country dynamics
  • Fig. 70 South Korea mRNA therapeutics contract development and manufacturing (CDMO) market estimates and forecast, 2020 - 2030 (USD Million)
  • Fig. 71 Latin America mRNA therapeutics contract development and manufacturing (CDMO) market estimates and forecast, 2020 - 2030 (USD Million)
  • Fig. 72 Brazil key country dynamics
  • Fig. 73 Brazil mRNA therapeutics contract development and manufacturing (CDMO) market estimates and forecast, 2020 - 2030 (USD Million)
  • Fig. 74 Mexico key country dynamics
  • Fig. 75 Mexico mRNA therapeutics contract development and manufacturing (CDMO) market estimates and forecast, 2020 - 2030 (USD Million)
  • Fig. 76 Argentina key country dynamics
  • Fig. 77 Argentina mRNA therapeutics contract development and manufacturing (CDMO) market estimates and forecast, 2020 - 2030 (USD Million)
  • Fig. 78 MEA mRNA therapeutics contract development and manufacturing (CDMO) market estimates and forecast, 2020 - 2030 (USD Million)
  • Fig. 79 South Africa key country dynamics
  • Fig. 80 South Africa mRNA therapeutics contract development and manufacturing (CDMO) market estimates and forecast, 2020 - 2030 (USD Million)
  • Fig. 81 Saudi Arabia key country dynamics
  • Fig. 82 Saudi Arabia mRNA therapeutics contract development and manufacturing (CDMO) market estimates and forecast, 2020 - 2030 (USD Million)
  • Fig. 83 UAE key country dynamics
  • Fig. 84 UAE mRNA therapeutics contract development and manufacturing (CDMO) market estimates and forecast, 2020 - 2030 (USD Million)
  • Fig. 85 Kuwait key country dynamics
  • Fig. 86 Kuwait mRNA therapeutics contract development and manufacturing (CDMO) market estimates and forecast, 2020 - 2030 (USD Million)
  • Fig. 87 Key company categorization
  • Fig. 88 Company market positioning
  • Fig. 89 Market participant categorization
  • Fig. 90 Strategy framework